OncoCyte (OCX)

• Market cap: $75.2M
• 1 day: -5.05%
• 5 days: -6.07%
• 1 month: -7.72%
• 3 months: 2.73%
• 6 months: -6.07%
• Year to date: 12.88%
• 1 year: -9.31%
• 5 years: -95.48%
• 10 years: -98.54%
• Sector: Healthcare
• Industry: Diagnostics & Research

About: OncoCyte Corp is a pioneering diagnostics technology company. Its mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes. The company develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancers. In addition, it also develops screening diagnostics as potential replacements for screening imaging procedures that do not meet the needs of patients, health care providers, or payers.

Employees: 49

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

500% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 1

100% more funds holding in top 10

Funds holding in top 10: 1 [Q3] → 2 (+1) [Q4]

80% more repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 5

25% more funds holding

Funds holding: 20 [Q3] → 25 (+5) [Q4]

2% less capital invested

Capital invested by funds: $20.4M [Q3] → $20M (-$396K) [Q4]

3.63% less ownership

Funds ownership: 53.6% [Q3] → 49.97% (-3.63%) [Q4]

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $4 52% upside
• Avg. target: $4.42 68% upside
• High target: $5 90% upside

3 analyst ratings

• positive: 2 67%
• neutral: 1 33%
• negative: 0 0%

Needham Mike Matson 44% 1-year accuracy 17 / 39 met price target	62% upside $4.25	Buy Reiterated	13 May 2025
Lake Street Thomas Flaten 100% 1-year accuracy 2 / 2 met price target	90% upside $5	Buy Initiated	28 Mar 2025
Stephens & Co. Mason Carrico 15% 1-year accuracy 4 / 27 met price target	52% upside $4	Equal-Weight Reiterated	26 Mar 2025